Financial Survey: ObsEva (NASDAQ:OBSV) versus Hillstream Biopharma (NASDAQ:CNTN)

ObsEva (NASDAQ:OBSV) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Institutional and Insider Ownership

17.5% of ObsEva shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for ObsEva and Hillstream Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0	0	0	0	0.00
Hillstream Biopharma	1	0	0	0	1.00

Given ObsEva’s higher probable upside, equities analysts plainly believe ObsEva is more favorable than Hillstream Biopharma.

Risk and Volatility

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Hillstream Biopharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Valuation and Earnings

This table compares ObsEva and Hillstream Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A
Hillstream Biopharma	N/A	N/A	-$35.92 million	($1.15)	-2.47

Hillstream Biopharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ObsEva and Hillstream Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Hillstream Biopharma	N/A	-31.50%	-24.72%

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.